HeartSciences Inc. reported its financial results for the three months ending July 31, 2025, revealing a modest revenue of $1,900, a significant increase from zero revenue in the same period last year. The company incurred a net loss of approximately $2.05 million, slightly higher than the $2.05 million loss reported in the prior year. The increase in revenue is attributed to the establishment of distributor relationships outside the U.S. as part of the ongoing development of the MyoVista wavECG device.
In terms of operational performance, HeartSciences saw a decrease in research and development expenses, which totaled $997,206, down 19% from $1.22 million in the previous year. This reduction is primarily due to decreased consulting costs following the completion of Phase 1 of the MyoVista Insights Cloud Platform. Selling, general, and administrative expenses rose slightly to $878,053, reflecting a $27,000 increase primarily due to higher stock compensation expenses. The company’s total operating expenses decreased by 10% to $1.88 million compared to the previous year.
HeartSciences has made strategic advancements, including the issuance of 1,317,689 units of Series D Preferred Stock and warrants, generating approximately $4.6 million in gross proceeds during the quarter. The company has also entered into multiple license agreements with Mount Sinai to commercialize AI-ECG algorithms, which are expected to enhance the clinical capabilities of its products. As of July 31, 2025, the company had cash and cash equivalents of $2.79 million, a notable increase from $1.1 million at the end of the previous fiscal year.
The company’s accumulated deficit reached $78.2 million, raising concerns about its ability to continue as a going concern. HeartSciences has indicated that it may need to raise additional capital to fund operations and achieve FDA clearance for its products. The company is currently exploring various financing options, including equity sales and strategic partnerships, to support its ongoing development and commercialization efforts.
Looking ahead, HeartSciences plans to submit its MyoVista wavECG device for FDA clearance in 2025, with expectations to launch its AI-ECG algorithms in the first half of 2026. The company remains focused on expanding its product offerings and enhancing its market presence, particularly in frontline healthcare environments where effective cardiac screening tools are in high demand.
About HeartSciences Inc.
HeartSciences Inc. develops AI-driven ECG solutions to enhance cardiac screening and diagnosis. Its core products include the MyoVista wavECG device and a cloud-based platform hosting AI-ECG algorithms for detecting heart dysfunction. Targeting healthcare settings worldwide, the company aims to improve early heart disease detection, expand ECG capabilities, and facilitate regulatory approval, offering a competitive, device-agnostic approach to cardiovascular diagnostics.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.